Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. Revolution Medicines is seeking a strategic, enterprise-minded Lifecycle Leader to lead the global lifecycle strategy for the daraxonrasib Lung Cancer program. This role is accountable for shaping and executing an integrated end-to-end molecule strategy — from pivotal development through commercialization and post-launch expansion — to maximize long-term patient and enterprise value. The Lifecycle Leader serves as the cross-functional integrator and strategic architect for daraxonrasib, aligning disease area priorities, development strategy, regulatory considerations, and commercialization planning into a unified global roadmap. This individual will lead the cross-functional Lifecycle Team, drive strategic trade-offs within a portfolio context, and ensure seamless execution across geographies and functions. The role requires deep commercialization expertise, including demonstrated NME launch leadership in oncology, and the ability to translate scientific progress into differentiated, launch-ready strategies that deliver meaningful impact for patients and sustained value for the organization.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive